Quantedge Capital Pte Ltd Takes Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Quantedge Capital Pte Ltd bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 75,500 shares of the company's stock, valued at approximately $598,000.

Several other large investors have also made changes to their positions in AMRX. Vanguard Group Inc. boosted its holdings in Amneal Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock valued at $117,548,000 after acquiring an additional 218,025 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Amneal Pharmaceuticals by 5.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock worth $39,531,000 after buying an additional 278,653 shares during the period. Geode Capital Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock worth $30,207,000 after buying an additional 26,536 shares in the last quarter. Nantahala Capital Management LLC raised its position in Amneal Pharmaceuticals by 37.3% in the 4th quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after buying an additional 995,586 shares during the last quarter. Finally, BlackBarn Capital Partners LP lifted its stake in Amneal Pharmaceuticals by 18.2% in the 4th quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company's stock valued at $22,572,000 after acquiring an additional 438,388 shares in the last quarter. Institutional investors own 31.82% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on AMRX shares. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays increased their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $11.50.

Amneal Pharmaceuticals Trading Down 0.6%

Shares of AMRX traded down $0.05 during mid-day trading on Tuesday, reaching $7.46. The company's stock had a trading volume of 592,811 shares, compared to its average volume of 1,441,699. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $9.48. The business has a 50-day simple moving average of $7.74 and a two-hundred day simple moving average of $8.08. The stock has a market cap of $2.34 billion, a P/E ratio of -10.95 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The firm had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This represents a 9.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. The trade was a 4.24% decrease in their position. The disclosure for this sale can be found here. 26.56% of the stock is owned by corporate insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.